Eluting

No data found

Search Eluting biology news at Google

Search Eluting biology news at Yahoo

Search Eluting biology news at Msn

Eluting at Biology Products

No data found

Search Eluting biology products at Google

Search Eluting biology products at Yahoo

Search Eluting biology products at Msn

Eluting at Biology Technology

No data found

Search Eluting biology technology at Google

Search Eluting biology technology at Yahoo

Search Eluting biology technology at Msn

Eluting at Medicine News

Drug-Eluting Stents Ensure Patency Of The Saphenous Vein Grafts

The new generation stents that are deigned for slow release of medication are found to be far more effective than conventional stents according to a recent study conducted on stents used for cardiac bypass // . It is also found to effectively prevent the overgrowth of scar tissue, thereby reducing incidence of restenosis (re-narrowing), heart attack and death. Stents can either be inser...

Bypass Surgery, Drug-eluting Stents Possess Similar Risk and Outcome

Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures// , according to researchers. The two also have similar outcomes three years after treatment. Patients with coronary arteries narrowed by atherosclerosis are often candidates for either bypass surgery to reroute the arteries'...

Drug Eluting Nanostructured Coatings Enable Targeted Drug Therapy for Orthopedic Patients

Drug delivery systems have progressed from the teaspoon to time-release capsules to drug-eluting stents . In a paper presented at the NSTI Nanotech 2007 Conference, researchers at the University of California, San Francisco demonstrate how they hav...

Eluting at Medicine Products

Cypher Sirolimus-eluting Coronary Stent

Description:The CYPHER Sirolimus-eluting Coronary Stent consists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, sirolimus elutes into the vessel wall and impedes the process of neointimal hyperplasia, thereby significantly reducing the incidence of in-stent restenosis....
Company:Cordis Corporation

TAXUS Express2 Over-the-wire Paclitaxel-Eluting Coronary Stent System

Description:The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3.75 mm in diameter....
Company:Boston Scientific Corporation

TAXUS Express2 Monorail Paclitaxel-Eluting Coronary Stent System

Description:The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3.75 mm in diameter....
Company:Boston Scientific Corporation

CoStar Paclitaxel-eluting Coronary Stent System

Description:BIOTRONIK AG will be the world wide sole distributor of CONOR Medsystems COSTAR paclitaxel stent. Radically different from conventional drug eluting stents, the CONOR Medsystems stent is the first non-surface-coated drug eluting stent designed to provide advanced drug delivery capabilities. CONOR Medsystems proprietary technologies allow release profiles to be tailored to optimize the dosing of a...
Company:Biotronik GmbH & Co.

Eluting at Medicine Technology

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...

Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents

Risk of Late Thrombosis is Minimized with Genous Stent BARCELONA, Spain, May 23, 2007 /PRNewswire/ -- The efficacy ofOrbusNeich's Genous(TM) Bio-engineered R stent compares favorablyto that of drug-eluting stents, while the risk of late thrombosisis minimized with the Genous stent, according to an interimanalysis of post-marketing data presented today by Robbert deWinter, M.D., Ph.D., at...

Abbott Announces Positive Nine-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Absorbable Stent Continues to Show Promise as Future-GenerationTechnology BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced positive results from ABSORB, the world's firstclinical trial evaluating the safety and performance of a fullybioabsorbable drug eluting stent platform for the treatment ofcoronary artery disease. Nine-month results from the first 30pati...

Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with NoLate Stent Thrombosis or Additional Major Adverse Cardiac EventsOut to Three Years BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ --Three-year data from the SPIRIT FIRST trial demonstrated noadditional Major Adverse Cardiac Events (MACE), and no late stentthrombosis in patients treated with either Abbott's XIENCE(TM) V...

Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principalinvestigators for the COSTAR II (CObalt Chromium STent withAntiproliferative for Restenosis) trial, the pivotal study for theCoStar(R) cobalt chromium paclitaxel-eluting coronary stent,presented today the clinical trial results of the study at EuroPCR2007. The investigators confirmed that the study failed to meet itsprimary endpoint...

More>>